Neurobiological pathways to childhood psychopathology : Population-based studies of cognition and behavior

In the past few decades, considerable advances have been made in understanding childhood psychopathology. This progress is the result of four primary developments in the field. First, both in the research and in the clinical framework, psychopathology has been conceptualized across a spectrum of severity of symptoms and impairment. Second, psychopathology has been studied in the context of young children’s real life parallel to referral settings. Third, studying child psychopathology in large-scale prospective epidemiological studies offers new insight into the etiology of child psychiatric disorders. And fourth, enormous progress has been made in understanding the nature of psychopathology and its biological underpinnings

Parte A: Divide et impera: tramite uno screening in silico che targhetta l'omodimerizzazione del fattore di processività di HCMV, ppUL44, sono state identificate piccole molecole inibenti la replicazione virale. ParteB: Identificazione del proteoma nucleare di tutti i virus umani tramite un'analisi completa della localizzazione nucleare classica.

Human cytomegalovirus (HCMV) è un agente patogeno principale di molte malattie in persone immunosoppresse, inclusi pazienti affetti da AIDS e sottoposti a trapianto, e nascituri congenitamente infetti. Le terapie ed i farmaci antivirali utilizzati per il trattamento dell’infezioni da HCMV presentano una serie di limitazioni, tra cui la bassa biodisponibilità, tossicità, e l’insorgenza di ceppi virali farmaco resistenti, rendendo cruciale la necessità di identificare nuovi target terapeutici efficaci. Studi sulle interazioni tra proteine virali (PPI) si sono rivelati alleati importanti per lo sviluppo di nuovi farmaci antivirali, in quanto questi ultimi possono inibire il ciclo vitale del virus interferendo con le attività delle proteine virali. La dimerizzazione del fattore di processività della DNA polimerasi, ppUL44, di HCMV è essenziale per il ciclo vitale del virus infatti necessaria per la replicazione del DNA virale mediata da oriLyt e può essere quindi considerata come un potenziale target terapeutico. Pertanto, in precedenza, tramite uno screening in silico sono state identificate 18 piccole molecole (Small Molecules, SMs) potenzialmente capaci di interferire con la omodimerizazzione di ppUL44. Saggi antivirali delle 18 SMs sul virus ricombinante . In questo lavoro sono riuscita a caratterizzare l’effetto di questi composti sulla viabilità e crescita cellulare, e quindi cominciare un’analisi preliminare del loro meccanismo di azione. Tutte hanno compromesso la replicazione dei virus reporter AD169 di HCMV ed una sua controparte resistente al GCV in maniera simile. Tra le 4 SMs scelte, B3, ha mostrato il Selectivity Index (SI) più alto e quindi l’unico composto ad essere ulteriormente analizzato. Siamo riusciti a dimostrare che B3 efficientemente inibisce lo strain virale AD169 di HCMV in saggi di Plaque Reduction (PRA). Come misurato tramite qPCR, B3 ha specificatamente inibito la sintesi del DNA virale a partire da 72 ore post infezione, come anche l’espressiIl nostro Gruppo di ricerca ha precedentemente identificato il proteoma nucleare di tutti i virus infettanti l’essere umano, distinguendo tra proteine virali che traslocano all’interno del nucleo della cellula infetta in modo IMPα/β1 dipendente o meno, combinando analisi bioinformatiche estese anche alla caratterizzazione funzionale delle sequenze di localizzazione nucleare (NLS) virali. Questo studio presenta l’opportunità senza precedenti di comparare la diversa interazione tra virus differenti con l’apparato di trasporto al nucleo della cellula infetta, con importanti implicazioni sullo sviluppo di nuovi target terapeutici antivirali a largo spettro. Una profonda analisi funzionale sui classici NLS (cNLS) putative identificati ci ha portato alla scoperta di più di 500 proteine codificanti cNLS. Siamo riusciti anche a fare una prima caratterizzazione del processo di import nucleare delle proteine Large T antigen (LTA) dei Polyomavirus (HPyV) e delle cNLS coinvolte. Nonostante i LT di 14 HPyV presentavano cNLS funzionali, queste erano molto diverse tra di loro sia in termini di struttura che di attività. Le attività delle cNLS hanno riflesso I livelli di accumulo nucleare delle proteine full-length, con l’attività più bassa associata alla cNLS di HPyV7. Nonostante molti HPyV codificano per una o più cNLS monopartite, 4 di esse presentavano cNLS bipartita. Chiaramente queste differenze strutturali influenzano affinità verso l’apparato IMPα/β1 dipendente ed il tropismo del virus. Inoltre, 2 tra le 26 cNLS con il punteggio di cNLS mapper più alto identificate con i nostri studi, sono altamente conservate e presentano vari ortologhi di due proteine, A19 e N2, della famiglia dei Poxivirdae. Entrambe le proteine localizzano nel nucleo della cellula ospite, in un pathway attivo IMPα/β1 dipendente, e la loro traslocazione nucleare viene inibita in presenza di mutazioni sito-specifico.  Human cytomegalovirus (HCMV) is a leading cause of severe diseases in immunocompromised individuals, including AIDS patients and transplant recipients, and in congenitally infected newborns. The utility of available drugs is limited by poor bioavailability, toxicity, and emergence of resistant strains. Therefore, it is crucial to identify new targets for therapeutic intervention. Among the latter, viral protein–protein interactions are becoming increasingly attractive. Since dimerization of HCMV DNA polymerase processivity factor ppUL44 plays an essential role in the viral life cycle, being required for oriLyt-dependent DNA replication, it can be considered a potential therapeutic target. We therefore previously performed an in silico screening and selected 18 small molecules (SMs) potentially interfering with ppUL44 homodimerization. Antiviral assays using recombinant HCMV TB4-UL83-YFP in the presence of the selected SMs led to the identification of four active compounds. In this work I have characterized the effect of such compounds on cell viability and growth and began a preliminary analysis of their mode of action. All of them impaired replication of an AD169-GFP reporter virus and its ganciclovir-resistant counterpart to a similar extend. Among the 4 selected SMs compound B3 exhibited the highest selectivity index (SI) and was further investigated. We could show that it also efficiently inhibited HCMV AD169 strain in plaque reduction assays (PRAs). As assessed by qPCR by Western blotting experiments, B3 specifically reduced viral DNA synthesis starting from 72 h post infection, consistent with the inhibition of viral gene expression starting from 48 h post infection by Western blotting experiments. Therefore, our data suggest that inhibition of ppUL44 dimerization could represent a new class of HCMV inhibitors, complementary to those targeting the DNA polymerase catalytic subunit or the viral terminase complex. Our research group previously defined the nuclear proteome of all human viruses, discriminating between viral proteins translocated in an IMPα/β1 dependent or independent process by combining bioinformatics analysis with extensive functional characterization of viral cNLSs. This study represents an unprecedented opportunity to compare how viruses differently interact with the host cell nuclear transport machinery, with important implications for the development of broad-range host targeted antivirals. In depth functional validation of identified putative classical nuclear localization signals (cNLSs) led to the discovery of more than 500 novel viral cNLS. We also report the first characterization of the nuclear import process of Human Polyomaviruses (HPyVs) Large T antigens (LT) as well as of the cNLS involved. Although LT from all 14 HPyVs bear a functional cNLS, the latter are extremely heterogenous, both in terms of activity and structural organization. Importantly, cNLS activity mirrored the levels of nuclear accumulation of full-length proteins, with lowest activity associated to HPyV7. Surprisingly, while most HPyVs bear one or more monopartite cNLS, four of them bear a bipartite cNLS. Clearly, such structural differences suggest an important role in conferring binding abilities to specific IMPα isoforms with potential implication for viral tropism determination. Furthermore, among the 26 top ranked cNLS based on cNLS mapper score, two extremely well conserved cNLS in orthologues of Vaccinia Virus proteins A19 and N2 were identified. Both proteins localized in the cell nucleus via energy and IMPα/β-dependent process, and their nuclear import could be abolished by site specific mutagenesis of the cNLSs, thus A19 and N2 mutant derivatives failed to localize in the nucleus

Linearity of Calibration Curves for Analytical Methods: A Review of Criteria for Assessment of Method Reliability

Calibration curve is a regression model used to predict the unknown concentrations of analytes of interest based on the response of the instrument to the known standards. Some statistical analyses are required to choose the best model fitting to the experimental data and also evaluate the linearity and homoscedasticity of the calibration curve. Using an internal standard corrects for the loss of analyte during sample preparation and analysis provided that it is selected appropriately. After the best regression model is selected, the analytical method needs to be validated using quality control (QC) samples prepared and stored in the same temperature as intended for the study samples. Most of the international guidelines require that the parameters, including linearity, specificity, selectivity, accuracy, precision, lower limit of quantification (LLOQ), matrix effect and stability, be assessed during validation. Despite the highly regulated area, some challenges still exist regarding the validation of some analytical methods including methods when no analyte-free matrix is available

Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver

© 2017 Elsevier B.V. The tyrosine kinase inhibitors sorafenib and imatinib are important in the treatment of a range of cancers but adverse effects in some patients necessitate dosage modifications. CYP3A4 has a major role in the oxidation of sorafenib to its N-oxide and N-hydroxymethyl metabolites and also acts in concert with CYP2C8 to mediate imatinib N-demethylation. CYP3A4 expression and function are impaired in patients with advanced liver disease, whereas the functions of CYP2C enzymes are relatively preserved. We evaluated the biotransformation of sorafenib and imatinib in well-characterized microsomal fractions from 17 control subjects and 19 individuals with hepatic cirrhosis of varying severity. The principal findings were that liver disease impaired the microsomal oxidation of sorafenib to its major metabolites to 40–44% of control (P < 0.01), whereas the N-demethylation of imatinib was relatively unimpaired. The impairments in sorafenib biotransformation were correlated with decreased serum albumin concentrations and increased serum bilirubin concentrations in patients with liver disease, but not with the overall grade of liver disease according to the Child-Pugh system. In contrast, there was no relationship between imatinib N-demethylation and clinicopathologic factors in liver disease patients. These findings were accounted for in terms of the differential roles of CYPs 3A4 and 2C8 in the intrinsic clearance of the drugs. CYP3A4 has the major role in the intrinsic clearance of sorafenib but plays a secondary role to CYP2C8 in the intrinsic clearance of imatinib. In agreement with these findings CYP2C protein expression and CYP2C8-mediated paclitaxel 6α-hydroxylation were unimpaired in cirrhotic livers. This information could be adapted in individualized approaches such as in vivo CYP3A4 phenotyping to optimize sorafenib safety and efficacy in cancer patients with liver dysfunction

An improved liquid chromatography tandem mass spectrometry (LC-MS/MS) method for quantification of dexmedetomidine concentrations in samples of human plasma

Dexmedetomidine (DMET) is a sedative, analgesic and anxiolytic with minimum adverse respiratory effects. An LC-MS/MS bioanalytical method has been developed and validated to accurately measure DMET concentrations in samples of human plasma. The method overcomes difficulties in the extraction and quantification of DMET due to the fact that it binds strongly to glass and plastic tubes, as well as solid phase extraction (SPE) cartridges. Human plasma (50 μL) was mixed with the internal standard (IS) (DMET-d4) solution (100 μL) and 0.1% formic acid (50 μL) and extracted using Oasis HLB 1 CC (30 mg) solid phase extraction (SPE) cartridges (Waters®). The glass tubes were coated with bovine serum albumin (BSA) 0.5% (20 μL) before eluting DMET and the IS. After evaporation under nitrogen at room temperature, the analytes were reconstituted in 20% acetonitrile in 0.1% formic acid in water and transferred to silanized glass vials. An electrospray ionisation (ESI) mass spectrometry method in positive mode was created and the precursor/product transitions (m/z) were 201.1 → 95.0 (DMET) and 204.9 → 99.0 (IS). The method was robust and fully validated based on the 2012 EMEA guideline for bioanalytical method validation in the concentration range of 0.5-20 ng/mL. Using this assay, we showed that DMET binds strongly to Extracorporeal Membrane Oxygenation (ECMO) circuits, consistent with expectations for small lipophilic compounds

Gestational Age at Birth and Risk of Developmental Delay: The Upstate KIDS Study

Objective—To model the association between gestational age at birth and early child development through 3 years of age. Study Design—Development of 5868 children in Upstate KIDS (New York State; 2008–2014) was assessed at 7 time-points using the Ages and Stages Questionnaire (ASQ). The ASQ was implemented using gestational age corrected dates of birth at 4, 8, 12, 18, 24, 30, and 36 months. Whether children were eligible for developmental services from the Early Intervention Program (EIP) was determined through linkage. Gestational age was based on vital records. Statistical models adjusted for covariates including sociodemographic factors, maternal smoking and plurality. Results——Compared to gestational age of 39 weeks, adjusted odds ratios (aOR) and 95% confidence intervals of failing the ASQ for children delivered at \u3c 32, 32–34, 35–36, 37, 38, and 40 weeks gestational age were: 5.32 (3.42, 8.28), 2.43 (1.60, 3.69), 1.38 (1.00, 1.90), 1.37 (0.98, 1.90), 1.29 (0.99, 1.67), 0.73 (0.55, 0.96), and 0.51 (0.32, 0.82). Similar risks of being eligible for EIP services were observed (aOR: 4.19, 2.10, 1.29, 1.20, 1.01, 1.00 (ref), 0.92, 0.78, respectively for \u3c 32, 32–34, 37, 38, 39 (ref), 40, 41 weeks). Conclusion—Gestational age was inversely associated with developmental delays for all gestational ages. Evidence from our study is potentially informative for low-risk deliveries at 39 weeks but it is notable that deliveries at 40 weeks exhibited further lower risk

Fetal bisphenol and phthalate exposure and early childhood growth in a New York City birth cohort

Background: Exposure to endocrine-disrupting chemicals such as bisphenols and phthalates during pregnancy may disrupt fetal developmental programming and influence early-life growth. We hypothesized that prenatal bisphenol and phthalate exposure was associated with alterations in adiposity through 4 years. This associations might change over time. Methods: Among 1091 mother–child pairs in a New York City birth cohort study, we measured maternal urinary concentrations of bisphenols and phthalates at three time points in pregnancy and child weight, height, and triceps and subscapular skinfold thickness at ages 1, 2, 3, and 4 years. We used linear mixed models to assess associations of prenatal individual and grouped bisphenols and phthalates with overall and time-point-specific adiposity outcomes from birth to 4 years. Results: We observed associations of higher maternal urinary second trimester total bisphenol and bisphenol A concentrations in pregnancy and overall child weight between birth and 4 years only (Beta 0.10 (95 % confidence interval 0.04, 0.16) and 0.07 (0.02, 0.12) standard deviation score (SDS) change in weight per natural log increase in exposure), We reported an interaction of the exposures with time, and analysis showed associations of higher pregnancy-averaged mono-(2-carboxymethyl) phthalate with higher child weight at 3 years (0.14 (0.06, 0.22)), and of higher high-molecular-weight phthalate, di-2-ethylhexyl phthalate, mono-(2-ethyl-5-carboxypentyl) phthalate, mono-(2-carboxymethyl) phthalate, and mono-(2-ethylhexyl) phthalate with higher child weight at 4 years (0.16 (0.04, 0.28), 0.15 (0.03, 0.27), 0.19 (0.07, 0.31), 0.16 (0.07, 0.24), 0.11 (0.03, 0.19)). Higher pregnancy-averaged high-molecular-weight phthalate, di-2-ethylhexyl phthalate, mono-(2-ethyl-5-carboxypentyl) phthalate, mono-(2-ethyl-5-hydroxyhexyl) phthalate, and mono-2(ethyl-5-oxohexyl) phthalate concentrations were associated with higher child BMI at 4 years (0.20 (0.05, 0.35), 0.20 (0.05, 0.35), 0.22 (0.06, 0.37), 0.20 (0.05, 0.34), 0.20 (0.05, 0.34)). For skinfold thicknesses, we observed no associations. Discussion: This study contributes to the evidence suggesting associations of prenatal exposure to bisphenols and high-molecular-weight phthalates on childhood weight and BMI.</p

New Frontiers of Corneal Gene Therapy

Corneal diseases are among the most prevalent causes of blindness worldwide. The transparency and clarity of the cornea are guaranteed by a delicate physiological, anatomic, and functional balance. For this reason, all the disorders, including those of genetic origin, that compromise this state of harmony can lead to opacity and eventually vision loss. Many corneal disorders have a genetic etiology, and some are associated with rather rare and complex syndromes. Conventional treatments, such as corneal transplantation, are often ineffective, and to date, many of these disorders are still incurable. Gene therapy carries the promise of being a potential cure for many of these diseases, with solutions and strategies that did not seem possible until a few years ago. With its potential to treat genetic disease by means of deletion, replacement, or editing of a defective gene, the challenge can also be extended to corneal disorders in order to achieve long-term, if not definitive, relief. The aim of this paper is to review the state of the art of the different gene therapy approaches as potential treatments for corneal diseases and the future perspectives for the development of personalized gene-based medicine